Skip to main content
Equibles

Taylor Schreiber

CEO

Shattuck Labs, Inc. (STTK)

Board Member

Shattuck Labs, Inc. (STTK)

Equibles does not estimate personal net worth.

Get an email with a short summary when Shattuck Labs, Inc. publishes a filing, an earnings call transcript or a press release.

Get STTK alerts

About Taylor Schreiber

Taylor Schreiber is recorded as CEO and Board Member at Shattuck Labs, Inc. (STTK). The newest filing on record that lists Taylor Schreiber as CEO and Board Member at Shattuck Labs, Inc. (STTK) is dated April 8, 2026. The proxy statement of Shattuck Labs, Inc. reports total compensation of $1,532,763 for Taylor Schreiber in fiscal 2025, including a base salary of $565,600. Disclosed compensation is on record for 6 fiscal years. Taylor Schreiber has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Shattuck Labs, Inc. on September 8, 2026. Shattuck Labs, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Shattuck Labs, Inc. includes George Golumbeski (Chairman), Andrew Neill (CFO), Stephen Stout (General Counsel) and 7 others.

Taylor Schreiber on recent calls

“So Shattuck is, these days, entirely focused on blocking DR3, which is the sole receptor for TL1A. This is a very simple axis where you have a single ligand TL1A binding to a single receptor, DR3.”
CEO, Wells Fargo 21st Annual Healthcare Conference ·
“We are very pleased that our lead clinical stage product candidate, SL-172154, has advanced to a stage where we are able to begin sharing clinical data from both our hematologic and solid tumor programs.”
CEO, Shattuck Labs, Inc. Q3 FY2023 Earnings Call ·
“2022 was an operationally focused year for Shattuck, and our clinical team did an excellent job of advancing 154, our lead clinical-stage Agonist Redirected Checkpoint or ARC product candidate.”
CEO, Shattuck Labs, Inc. Q4 FY2022 Earnings Call ·
“2022 has been an operationally focused year for Shattuck, and our clinical team has done an excellent job of advancing 154, our lead clinical stage agonist redirected checkpoint or ARC compound.”
CEO, Shattuck Labs, Inc. Q3 FY2022 Earnings Call ·
“Today’s earnings call is the first since our initial public offering in October of 2020 and I am exceptionally proud of the milestones our team has achieved since that time.”
CEO, Shattuck Labs, Inc. Q2 FY2021 Earnings Call ·

Affiliation history

Company network

Leadership on record at Shattuck Labs, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Shattuck Labs, Inc. (STTK) $565,600 $1,532,763
2024 Shattuck Labs, Inc. (STTK) $560,000 $3,216,407
2023 Shattuck Labs, Inc. (STTK) $525,000 $1,034,408
2022 Shattuck Labs, Inc. (STTK) $525,000 $1,465,211
2021 Shattuck Labs, Inc. (STTK) $525,000 $744,451
2020 Shattuck Labs, Inc. (STTK) $394,531 $2,095,466

Recent activity